Because the targeted therapies to BRAF mutations and HER2 amplifications have significant survival benefit in various human cancers [10,18,19], treatment with anti-BRAF and anti-HER2 agents may be a good therapeutic strategy to improve survival in CRC patients with wild type KRAS harboring BRAF mutations or HER2 amplifications and who also have primary or secondary resistance to anti-EGFR treatment. The gene discussed is BRAF; the disease is colorectal carcinoma.